Genmab/$GMAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Genmab
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Ticker
$GMAB
Sector
Primary listing
Employees
2,639
Headquarters
Copenhagen, Denmark
Website
Genmab Metrics
BasicAdvanced
$19B
1.41
$21.62
0.82
-
Price and volume
Market cap
$19B
Beta
0.82
52-week high
$33.65
52-week low
$17.24
Average daily volume
2.2M
Financial strength
Current ratio
6.216
Quick ratio
6.196
Long term debt to equity
2.49
Total debt to equity
2.791
Interest coverage (TTM)
49.22%
Profitability
EBITDA (TTM)
1,327.422
Gross margin (TTM)
94.54%
Net profit margin (TTM)
37.59%
Operating margin (TTM)
34.95%
Effective tax rate (TTM)
11.77%
Revenue per employee (TTM)
$1,380,000
Management effectiveness
Return on assets (TTM)
13.26%
Return on equity (TTM)
28.12%
Valuation
Price to earnings (TTM)
1.413
Price to revenue (TTM)
0.528
Price to book
23.04
Price to tangible book (TTM)
38.24
Price to free cash flow (TTM)
1.827
Free cash flow yield (TTM)
54.72%
Free cash flow per share (TTM)
16.712
Growth
Revenue change (TTM)
32.97%
Earnings per share change (TTM)
77.72%
3-year revenue growth (CAGR)
31.40%
10-year revenue growth (CAGR)
40.59%
3-year earnings per share growth (CAGR)
31.80%
10-year earnings per share growth (CAGR)
33.13%
What the Analysts think about Genmab
Analyst ratings (Buy, Hold, Sell) for Genmab stock.
Bulls say / Bears say
Genmab announced encouraging Phase II results for Arzerra in untreated CLL, with overall response rates of 77% and 73%, suggesting promise as a first-line treatment (Reuters)
Johnson & Johnson’s Q2 2025 earnings benefited from Darzalex, which delivered $3.54 billion in sales and led J&J to increase its full-year sales guidance to $93.2–$93.6 billion, supporting Genmab’s future royalty income (Reuters)
Genmab’s March deal allowed it to shift resources from HexaBody-CD38 to its late-stage proprietary pipeline, strengthening confidence in wholly owned assets like Rina-S and acasunlimab, both now in Phase 3 (Genmab)
J&J’s decision to discontinue HexaBody-CD38 forced Genmab to terminate development, highlighting pipeline risk and the loss of near-term revenue diversification opportunities (Genmab)
Morphosys AG has filed a patent infringement lawsuit against Genmab and Janssen over daratumumab, introducing legal uncertainties and possible royalty obligations for Genmab’s leading product (Reuters)
Genmab’s shares dropped to their lowest since mid-2003 despite increased retail interest, showing significant investor doubts about its valuation and growth outlook (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
Genmab Financial Performance
Revenues and expenses
Genmab Earnings Performance
Company profitability
Genmab News
AllArticlesVideos
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
Business Wire3 days ago
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
Business Wire3 weeks ago
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
Benzinga3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Genmab stock?
Genmab (GMAB) has a market cap of $19B as of October 21, 2025.
What is the P/E ratio for Genmab stock?
The price to earnings (P/E) ratio for Genmab (GMAB) stock is 1.41 as of October 21, 2025.
Does Genmab stock pay dividends?
No, Genmab (GMAB) stock does not pay dividends to its shareholders as of October 21, 2025.
When is the next Genmab dividend payment date?
Genmab (GMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Genmab?
Genmab (GMAB) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.